| Cat.No. | Name | Information |
|---|---|---|
| M10249 | Teduglutide | Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue used for the treatment of short-bowel syndrome. |
| M31216 | FC382K10W15 TFA | FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research. |
| M31107 | Pegapamodutide | Pegapamodutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in studies related to type II diabetes and obesity. |
| M31032 | V-0219 hydrochloride | V-0219 hydrochloride (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 hydrochloride can be used for obesity-associated diabetes research. |
| M31030 | Albiglutide TFA | Albiglutide TFA, a glucagon-like peptide (GLP)-1 mimetic, is a long acting GLP-1 receptor agonist. Albiglutide TFA significantly reduces glycosylated hemoglobin (A1C). Albiglutide TFA can be used for type 2 diabetes (T2D) research. Albiglutide TFA is generated by the genetic fusion of a DPP-4-resistant GLP-1 dimer to human albumin. |
| M31028 | VU0453379 hydrochloride | VU0453379 hydrochloride is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM. |
| M30792 | V-0219 | V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 can be used for obesity-associated diabetes research. |
| M30166 | GLP-1R Antagonist 1 | GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM. |
| M29807 | GLP-2(3-33) | GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC50=5.8 nM). |
| M29660 | Ecnoglutide | Ecnoglutide (XW003) is a glucagon-like peptide 1 (GLP-1) receptor agonist. |
| M29593 | GLP-1 receptor agonist 9 | GLP-1 receptor agonist 9 is a GLP-1 receptor agonist, example 7, extracted from WO2020234726 A1. |
| M29583 | TT-OAD2 | TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 has the potential for diabetes treatment. |
| M29401 | GLP-2(1-33)(human) | GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the GLP-2 receptor and stimulate the growth of intestinal epithelium. |
| M28746 | VU0453379 | VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM. |
| M28035 | TT-OAD2 free base | TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment. |
| M22299 | Efpeglenatide | Efpeglenatide is an exendin-based GLP-1 receptor agonist that can be used in studies related to type 2 diabetes. |
| M13972 | Semaglutide TFA | Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment. |
| M11428 | LSN3318839 | LSN3318839 is an orally active allosteric modulator of glucagon-like peptide-1 receptor (GLP-1R). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
